In the coming years, it is expected that the Americas IBS Treatment Market will advance with higher growth rate as compared to previous years. Rising pressure to curb healthcare costs has fuelled the growth of the market for IBS Treatment Market. The Americas IBS treatment market is expected to grow at a CAGR of 9.3% during the forecast period 2017-2023.
MarketResearchFuture.com adds “IBS Treatment Market – 2018 Americas Analysis, Growth, Trends and Opportunities Research Report forecasting to 2023” reports to its database.
The Americas region is divided into North America and South America. North America command the largest market of IBS treatment owing to the well presence of health care structure, government support, various research and development programs, increasing sensitivity and specificity for diagnosing IBS, aware and concerned individual, and presence of well-developed clinical laboratories. Moreover, presence of strong economic condition, and focus of research institutions on updating technology for new and advanced IBS treatment fuel the growth of market in this region. Also, the countries in this region have multiple companies which are involved in the IBS treatment business. North America is further divided into the U.S. and Canada. Both of these countries have good economic growth and great standard of living. According to a report published by the International Foundation for Functional Gastrointestinal Disorders, in 2016, functional gastrointestinal (GI) and motility disorders are the most common GI disorders which accounted for 1 in 4 people or more in the United States.
Major Players in the IBS treatment Market:
Some of the key players in this market are Allergan Plc (Ireland), Sucampo Pharmaceuticals (U.S.), Ironwood Pharmaceuticals, Inc. (U.S.), Astellas Pharma Inc. (Japan), Valeant Pharmaceuticals (Canada), Abbott Laboratories (U.S.), Synergy Pharmaceuticals, Inc. (U.S.), Ardelyx, Inc. (U.S.), Nestle (Switzerland), Sebela Pharmaceuticals (Ireland), Probi (Sweden), Alfasigma USA, Inc. (Italy), RedHill Biopharma Ltd. (Israel), AstraZeneca (U.K), Ipsen (France), Novartis AG (Switzerland), Takeda Pharmaceutical Company Ltd (Japan), Synthetic Biologics, Inc. (U.S.), Protagonist Therapeutics Inc. (U.S.), Pfizer Inc (U.S.), Lexicon Pharmaceuticals, Inc. (U.S.), Innovate Biopharmaceuticals (U.S.), 4D pharma plc (U.K).
You can get easy access to sample report here, please click: https://www.marketresearchfuture.com/sample_request/5555 .
Considering the Americas irritable bowel syndrome treatment market, there are two main regions: North America, and South America. North America consists of United States and Canada. United States holds largest market share due to the increasing burden of diseases, the share for functional gastrointestinal disorder is also increasing. According to a report published by the International Foundation for Functional Gastrointestinal Disorders, in 2016, functional gastrointestinal (GI) and motility disorders are the most common GI disorders which accounted for 1 in 4 people or more in the United States.
Canada is the second-largest market for irritable bowel syndrome owing to presence of patient population. Moreover, Increasing investment by organizations in the field of irritable bowel syndrome serves as a significant driver for the Canada, the market of IBS is expected to grow at a CAGR of 6.1%.
North America holds the major share of the market whereas, South America shows the fastest growth across the Americas region owing to the presence of an opportunity for the development of the market.
There are wide market for irritable bowel syndrome treatment in the Americas owing to increasing prevalence of patients suffering with anxiety, people feel the effects of stress in many way and one of the common symptom is irritable bowel syndrome. Anxiety can worsen symptoms of abdominal cramps and pain and make one feel sick in the stomach. Rising prevalence of population suffering with anxiety are the leading causes for the growth of Americas IBS market. According to updated report by Anxiety and Depression Association of America, in 2017, approximately 30 % of the adult population in North America has anxiety disorder issues. Presence of huge patient population with anxiety, have increased the chance of occurrence IBS in this region. Thus, big players are focusing on better treatment option in order to serve the patient suffering from irritable bowel syndrome.
Taste the market data and market information presented through more than 40 market data tables and figures spread over 69 pages of the project report. Avail the in-depth table of content TOC & market synopsis on “IBS treatment market research report– Americas forecast till 2023.”
The Americas IBS treatment market is segmented on the basis of types, drugs type, and end user. On the basis the types, it is segmented into IBS-D, IBS-C, IBS-M. On the basis of the drug type, it is segmented into lubiprostone, linaclotide, eluxadoline, rifaximin, alosetron, and others. On the basis of the end users, it is segmented into hospitals, clinics, and research laboratories.
Any query or specific requirement? Ask to our industry expert, please click: https://www.marketresearchfuture.com/enquiry/5555 .
What makes our report unique?
1) An extensive research study on the Americas IBS Treatment market, and its entire ecosystem, describes the market trends, drivers, restraints and opportunities of the IBS Treatment market.
2) We provide you the longest possible market segmentation based on type of products, procedures and geography and describe the market share region wise.
3) The report gives a bird eyes view on the competitive landscape which includes mergers and acquisitions, collaborations, market strategies, and new product launches.
Chapter 1. Report Prologue
Chapter 2. Market Introduction
Chapter 3. Research Methodology
Chapter 4. Market Dynamics
Chapter 5. Market Factor Analysis
Chapter 6. Americas IBS Treatment Market, By Type
Chapter 7. Americas IBS Treatment Market, By Drug Type
Chapter 8. Americas IBS Treatment Market, By End User
Chapter 9. Americas IBS Treatment by Region
Chapter 10. Company Landscape
Chapter 11. Company Profiles
Chapter 12. Conclusion
Chapter 13. Appendix
…CONTINUED FOR TOC
Feel free to get in touch for discounts and customized details, please click: https://www.marketresearchfuture.com/check-discount/5555 .
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Company Name: Market Research Future
Contact Person: Akash Anand
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune –